The invention relates to using cell free nucleosome levels to identify patients at risk of developing a NETosis associated adverse reaction to the infection. The methods are used to monitor the progress of a disease and assigning a risk of an adverse outcome in a patient suffering from an infection.

Methods for diagnosing a subject as a candidate for removal of a solid tumor without preoperative chemoradiation therapy, and methods for treating patients having solid tumors, who have one or more of genomic instability, elevated double stranded DNA breaks, elevated gamma-H2AX foci, or elevated replication stress and/or double stranded break-signalling (DSB-signalling) biomarkers in peripheral blood lymphocytes (PBLs) are provided herein.

The invention concerns KDM5A inhibitors for use in prevention or treatment of idiopathic inflammatory myopathies such as polymyositis, dermatomyositis, necrotizing autoimmune myopathy, and in particular sporadic inclusion body myositis, and diagnosis of these diseases based on KDM5A expression levels in muscle tissue. The invention further concerns pharmaceutical compositions comprising KDM5A inhibitors for use in prevention or treatment of idiopathic inflammatory myopathies such as polymyositis, dermatomyositis, necrotizing autoimmune myopathy, and in particular sporadic inclusion body myositis.

Disclosed are methods of measuring the amount of exposure of a host to a DNA double-stranded break (DSB)-causing agent by determining the ratio of the quantity of γ-H2AX to the quantity of total H2AX in a biological sample from the host as compared to the ratio of the quantity of γ-H2AX to the quantity of total H2AX in a positive control biological sample that has been exposed to a known amount of a DSB-causing agent. Related kits and methods of quantifying DSBs in a test biological sample are also disclosed.

The invention relates to cell free nucleosomes as biomarkers in plasma samples for vascular or haematological cancers.

Disclosed are a nanoplasmonic biosensor for detecting an autophagy marker with high sensitivity using a plasmon resonance effect, and a method of detecting an autophagy marker and a method of screening a cancer therapeutic agent using the same.

The invention provides methods, compositions, and kits for characterizing open chromatin by dual DNA/protein tagging.

A method for determining the health status of an elderly individual by testing the sample extracted from the individual for the presence of biomarkers, the bio markers being autoantibodies to antigens comprising MAPK13, CD96, FKBP3, PPM1A, PHLDA1, GLRX3, FEN1 and AURKA, wherein the antigens may further comprise one or more of UBE2I, AAK1, YARS, ASPSCR1, CASP10, FHOD2, TCL1A and MAP4, wherein PHLDA1 and CD96 correspond to healthy, AURKA, FEN1, CASP10 and AAK1 correspond to intermediate health, and UBE2I, YARS, ASPSCR1, FHOD2, TCL1A, MAP4, MAPK13, FKBP3, PPM1A and GLRX3 correspond to unhealthy.

The present invention relates to a pharmaceutical composition for inhibiting the resistance of liver cancer to sorafenib and enhancing an anticancer effect, comprising an Estrogen-related receptor γ (ERRγ) inhibitor as an active ingredient. The present invention can be effectively used as a pharmaceutical composition for treating sorafenib-resistant advanced liver cancer.

The invention provides a method for optimizing isHCR for multiplexed labeling, which combines binder-biomolecule interactions with hybridization Chain Reaction (HCR).